



*Improving life from the inside out*

Radius  
300 Technology Square, 5th Floor  
Cambridge, MA 02139  
(617) 551-4700  
(617) 551-4701 Fax  
[www.radiuspharm.com](http://www.radiuspharm.com)

**FOR IMMEDIATE RELEASE**

**Contact:**

Nick Harvey  
Chief Financial Officer  
(617) 551-4704

**Radius Presents Positive Results from Phase IB Clinical Trial of BA058 and Preclinical Study of RAD1901 at the Endocrine Society 2007 Annual Meeting**

—PTHrP analog, BA058, is safe and well-tolerated in healthy postmenopausal women—  
—Novel SERM, RAD1901, demonstrates efficacy in animal model of vasomotor symptoms—

*CAMBRIDGE, Mass., June 8, 2007*— Radius presented positive data from clinical and preclinical studies in two poster sessions at the 89th Annual Meeting of the Endocrine Society (ENDO 07), held in Toronto June 2-5, 2007.

Data from a Phase IB clinical trial of BA058, Radius' lead product for osteoporosis, show that BA058 is safe and well-tolerated in healthy postmenopausal women. Data from preclinical studies of RAD1901 demonstrate efficacy in animal models of vasomotor symptoms (hot flashes).

**BA058 Phase IB Trial Results**

The Phase IB clinical trial of the company's patented PTHrP analog, BA058, was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of BA058. In this study, consenting healthy postmenopausal women from 50 to 80 years of age were randomized to 5, 20, 40, or 80 micrograms of BA058 or placebo administered by subcutaneous injection once daily for seven days. BA058 was well tolerated at all doses studied and did not induce dose-dependent hypercalcemia or bone resorption. In addition, the study demonstrated early evidence of an increase in bone formation markers over seven days of exposure to BA058.

“BA058 is a PTHrP analog synthesized for greater efficacy in bone formation than PTH, limited effect on bone resorption, absence of hypercalcemia at effective doses, and

chemical stability,” said Louis O’Dea, MD, Chief Medical Officer of Radius. “The preclinical and Phase I programs have demonstrated BA058’s safety as well as its ability to induce bone formation without inducing resorption or hypercalcemia, supporting its further clinical development as a potentially more effective and more convenient anabolic agent for treating patients with osteoporosis.”

### **RAD1901 Preclinical Results**

The preclinical study of the company’s novel SERM, RAD1901, was designed to evaluate efficacy in an animal model of vasomotor symptoms. This study demonstrated that RAD1901 prevented vasomotor symptoms, prevented bone loss, and exhibited antagonist activity on the breast and uterus in animal models.

“In addition to the efficacy of RAD1901 demonstrated in the hot flash model, we observed a bone-protective effect mediated by a decrease in bone resorption, suggesting its potential to reduce the hot flashes associated with menopause while improving bone integrity, without stimulating breast or uterine tissues,” stated Gary Hattersley, PhD, Senior Director of Research at Radius.

The two abstracts presented at ENDO were:

- Abstract P2-137  
“BA058, a Novel Analog of Human Parathyroid Hormone-Related Peptide (PTHrP), Induces Evidence of Bone Formation Without Evidence of Bone Resorption Over 7 Days of Exposure”  
Presenter: Louis St. L. O’Dea
- Abstract P1-415  
“RAD1901, a Novel SERM, has Efficacy in an Animal Model of Vasomotor Symptoms”  
Presenter: Gary Hattersley

### **About BA058**

There is increasing evidence that PTHrP (parathyroid hormone-related protein) is a critical cytokine for promoting new bone formation, with a distinct role from PTH (parathyroid hormone), which regulates calcium homeostasis and bone resorption. BA058 is an analog of human PTHrP (hPTHrP) in Phase II clinical trials for the treatment of osteoporosis in postmenopausal women. BA058 is designed to build bone without inducing hypercalcemia or significant resorption.

### **About RAD1901**

RAD1901 is a novel, tissue-selective estrogen receptor modulator (SERM) currently in preclinical evaluation for the treatment and prevention of hot flashes (vasomotor symptoms) and osteoporosis. RAD1901 is distinctive from other SERMs in its unique biological profile, combined with its significant ability to penetrate the blood-brain barrier, which enables RAD1901 to function as an estrogen agonist within the central nervous system. Preclinical studies suggest that RAD1901 has the potential to reduce the hot flashes associated with menopause and to improve bone integrity without stimulating breast or uterine tissues.

### **About Osteoporosis**

Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip-fracture patients enter long-term care, and half of this group never returns to living independently.

### **About Vasomotor Symptoms (Hot Flashes)**

Hot flashes are a common symptom during menopause, with more than 75% of women experiencing them during the menopause transition, for a median duration of four years. These symptoms can disrupt sleep and interfere with quality of life. An estimated two million women undergo menopause every year in the U.S., with a total population of 50 million postmenopausal women. In addition, most women receiving systemic therapy for breast cancer suffer hot flashes, often with more severe or prolonged symptoms. Treatment with estrogen or hormone replacement therapy (ERT or HRT) is the standard of care for many women suffering hot flashes, but due to concerns about the potential long-term risks and contraindications, there is a significant need for new therapeutic options.

### **About Radius ([www.RADIUSPHARM.COM](http://www.radiuspharm.com))**

Radius is a product-driven pharmaceutical company that is a leader in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Based in Cambridge, Massachusetts, the company was formed in November 2003 and is privately held.

© 2007 RADIUS HEALTH INC.

###